Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ONO-4685 is an investigational anti-PD-1/CD3 bispecific antibody being developed for the treatment of relapsed or refractory T-cell lymphoma. It binds specifically to human PD-1 and CD3. PD-1 is an inhibitory receptor expressed on activated T and B cells, as well as on malignant T-cells in some subtypes of T-cell lymphomas. CD3 is a component protein of the T-cell receptor. As a CD3-bispecific antibody, ONO-4685 engages T-cells with malignant cells to induce anti-tumor activity. The drug is administered intravenously and is currently being evaluated in Phase 1 clinical trials.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on keyhole limpet hemocyanin + ONO-4685.